LAVA Therapeutics
Price & Volume
Stats
See moreOpen | $1.62 |
Previous Close | $1.59 |
Day Range | $1.60-$1.62 |
52W Range | $0.85-$2.09 |
Market Cap | $41.8M |
Shares Short | 98,649 |
Financials
See moreRevenue (12 Mos) | $4.9M |
Revenue Growth (YoY) | 1,313.6% |
Gross Profit (12 Mos) | -$19.5M |
Diluted EPS | -$1.06 |
News
See moreYahoo Finance • 2 months ago
LAVA Therapeutics GAAP EPS of -$0.32 misses by $0.06
Yahoo Finance • 2 months ago
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Yahoo Finance • 2 months ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
Yahoo Finance • 2 months ago
XOMA Royalty to acquire cancer drug developer LAVA Therapeutics
About
CEO | Mr. Stephen Allen Hurly M.B.A., M.Sc. |
Address | Yalelaan 62, Utrecht, Netherlands, 3584 CM |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 34 |
